v3.26.3
Schedule of Significant Expense Categories (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Total revenues $ 2,290,072 $ 114,574 $ 2,599,568 $ 831,287
Other research and development programs 2,070,033 2,707,777 6,875,816 5,906,118
Non-program expenses [1] 954,306 792,412 2,815,783 2,528,542
Personnel costs 1,022,415 633,880 3,226,679 2,746,787
Stock-based compensation 74,094 53,256 197,637 189,463
Total segment operating income (loss) (868,525) (3,361,040) (7,560,235) (7,855,578)
Other income (loss) [2] 202,333 174,208 599,554 598,157
Net income (loss) (666,192) (3,186,832) (6,960,681) (7,257,421)
Reportable Segment [Member] | Lead Clinical Candidate [Member]        
Segment Reporting [Line Items]        
Other research and development programs [3] 1,089,005 1,440,851 3,887,033 2,490,471
Reportable Segment [Member] | Other Research and Development Programs [Member]        
Segment Reporting [Line Items]        
Other research and development programs [3] $ 18,777 $ 555,215 $ 32,671 $ 731,602
[1] Includes general and administrative expenses, information technology, infrastructure, facilities, intellectual property, and legal and professional fees.
[2] Includes interest income and income tax expense. 
[3] Includes external research and development expenses.